Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia - Concepedia

Concepedia

Publication | Open Access

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

DOI Full Paper Access

296

Citations

23

References

2012

Year

Robert J. Kreitman, Martin S. Tallman, Tadeusz Robak, Steven Coutré, Wyndham H. Wilson, Maryalice Stetler‐Stevenson, David J. FitzGerald, Robert J. Lechleider, Ira Pastan

Journal of Clinical Oncology

Abstract

Moxetumomab pasudotox at doses up to 50 μg/kg QOD ×3 has activity in relapsed/refractory HCL and has a safety profile that supports further clinical development for treatment of this disease.

References

	Year	Citations

Page 1